{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:24:08Z","timestamp":1792257848323,"version":"4.4.0"},"reference-count":19,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.5582\/ddt.2025.01093","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T22:08:38Z","timestamp":1765577318000},"page":"431-434","source":"Crossref","is-referenced-by-count":1,"title":["Clinical significance of imeglimin in older patients with type 2 diabetes: Analysis of a national database and a long-term case suggesting the potential for sarcopenia prevention"],"prefix":"10.5582","volume":"19","author":[{"given":"Atsushi","family":"Ishimura","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacy Assessment, Hoshi University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department of Seihikarigaoka Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ogino","sequence":"additional","affiliation":[{"name":"Division of Life Science Pharmaceutics, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017; 16:21.","DOI":"10.1186\/s40200-017-0302-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Motohashi N, Minegishi K, Aoki Y. Inherited myogenic abilities in muscle precursor cells defined by the mitochondrial complex I-encoding protein. Cell Death Dis. 2023; 14:689.","DOI":"10.1038\/s41419-023-06192-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kabra UD, Jastroch M. Mitochondrial dynamics and insulin secretion. Int J Mol Sci. 2023; 24:13782.","DOI":"10.3390\/ijms241813782"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M, Kenanidis E, Potoupnis M, Tsiridis E, Goulis DG. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and meta-analysis. Calcif Tissue Int. 2020; 107:453-463.","DOI":"10.1007\/s00223-020-00742-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yokoyama H, Araki S, Yamazaki K, Kawai K, Shirabe SI, Oishi M, Kanatsuka A, Yagi N, Kabata D, Shintani A, Maegawa H. Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66). BMJ Open Diabetes Res Care. 2022; 10:e002727.","DOI":"10.1136\/bmjdrc-2021-002727"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, Moller DE, Hallakou-Bozec S. Reduced lactic acidosis risk with imeglimin: Comparison with metformin. Physiol Rep. 2022; 10:e15151.","DOI":"10.14814\/phy2.15151"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021; 23:664-673.","DOI":"10.1111\/dom.14277"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab. 2021; 4:e00211.","DOI":"10.1002\/edm2.211"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine \u00c9, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015; 64:2254-2264.","DOI":"10.2337\/db14-1220"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fouqueray P, Leverve X, Fontaine E, Baqui\u00e9 M, Wollheim C, Lebovitz H, Bozec S. Imeglimin-a new oral antidiabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab. 2011; 2:126.","DOI":"10.4172\/2155-6156.1000126"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yanagita I, Fujihara Y, Iwaya C, <i>et al<\/i>. Low serum albumin, aspartate aminotransferase, and body mass are risk factors for frailty in elderly people with diabetes-a cross-sectional study. BMC Geriatr. 2020; 20:200.","DOI":"10.1186\/s12877-020-01601-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Velissaris D, Pantzaris N, Koniari I, Koutsogiannis N, Karamouzos V, Kotroni I, Skroumpelou A, Ellul J. C-reactive protein and frailty in the elderly: A literature review. J Clin Med Res. 2017; 9:461-465.","DOI":"10.14740\/jocmr2959w"},{"key":"13","unstructured":"13. Ministry of Health, Labour and Welfare. National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data. Available from: <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html<\/i> (accessed 2025-8-20)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Niida Y, NishiokaY, Myojin T, Noda T, Takahashi Y, Imamura T. Trends in Diabetic Medication Use and Hypoglycemia Incidence Among Older Adults in Japan: A Retrospective Observational Study and a 10-Year Analysis Based on Level of Care Need Using Linked Medical and Long-Term Care Data. Cureus. 2025; 17:e87486.","DOI":"10.7759\/cureus.c252"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Aoyama K, Okada A, Kaneko H, Azegami T, Suzuki Y, Meguro S, Fujiu K, Takeda N, Morita H, Node K, Yamauchi T, Nangaku M, Takeda N, Yasunaga H, Hayashi K. Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database. Diabetes Obes Metab. 2025; 28:701-710.","DOI":"10.1111\/dom.70255"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Morley JE, Malmstrom TK, Rodriguez-Ma\u00f1as L, Sinclair AJ. Frailty, sarcopenia, and diabetes. J Am Med Dir Assoc. 2014; 15:853-859.","DOI":"10.1016\/j.jamda.2014.10.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007; 167:635-641.","DOI":"10.1001\/archinte.167.7.635"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Akbaraly TN, Hamer M, Ferrie JE, Lowe G, Batty GD, Hagger-Johnson G, Singh-Manoux A, Shipley MJ, Kivim\u00e4ki M. Chronic inflammation as a determinant of future aging phenotypes. CMAJ. 2013; 185:E763-E770.","DOI":"10.1503\/cmaj.122072"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010; 11:1509-1526.","DOI":"10.3390\/ijms11041509"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01093\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:19:57Z","timestamp":1768018797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01093\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01093","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01093"}}